ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Effects of Arsenic on Keratinocytes in a Skin Equivalent Model

This study is currently recruiting participants.
Verified by National Taiwan University Hospital, November 2004

Sponsored by: National Taiwan University Hospital
Information provided by: National Taiwan University Hospital
ClinicalTrials.gov Identifier: NCT00166946
  Purpose

We popose that arsenic-induced lymphocytes dysfunction plays an important role in biological mechanisms of arsenical Bowen’s disease.


Condition Intervention
Bowen Disease
Procedure: foreskin from healthy adults for organotypic culture

MedlinePlus related topics:   Arsenic   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Educational/Counseling/Training, Randomized, Open Label, Uncontrolled, Single Group Assignment
Official Title:   Effects of Arsenic on Keratinocytes in a Skin Equivalent Model

Further study details as provided by National Taiwan University Hospital:

Primary Outcome Measures:
  • we collect foreskin from healthy adults

Estimated Enrollment:   20
Study Start Date:   June 2005
Estimated Study Completion Date:   January 2008

Detailed Description:

Arsenical cancers (comprising skin, bladder, kidney, lung, colon and liver malignancies) were prevalent in southwestern coast of Taiwan where the artesian water was contaminated with high concentration of arsenic. Skin is a main target of arsenical poisoning. The cutaneous manifestations of chronic arsenism can take form as hyperpigmentation, hypopigmentation, arsenical keratosis and arsenical skin cancers. The most popular arsenical skin cancer is Bowen’s disease, which is a carcinoma in situ of skin and often confined to sun-protected skin. Pathologically, there are several characteristics present in Bowen’s disease: (1) abnormal cell proliferation and carcinogenesis in keratinocytes; (2) dysplasia and apoptosis at the lesion; (3) integrin deficiency/defect in the basal cells of the skin; (4) dysfunctions in peripheral immune cells. Our pervious results indicated that arsenic affected cell cycle regulation by influencing the proliferation and apoptosis of keratinocytes. Furthermore, we found that integrins were deficient in basal layer of lesional and perilesional sites of Bowen’s disease as demonstrated by immunohistochemistry. The integrin deficiency in Bowen’s disease might lead to abnormality of cell cycle regulation, differentiation and carcinogenesis. In addition, arsenic can destruct lymphocytes to cytokine regulation and induce lymphocytes apoptosis. We propose that arsenic-induced lymphocytes dysfunction plays an important role in biological mechanisms of arsenical Bowen’s disease. There are many regulatory mechanisms involved in progression of chemical carcinogenesis, including the reactions among carcinogen and target cells, supporting cells and immune interactions. Therefore, this study is to investigate these skin cell-cell interactions induced by arsenic using an organotypic epidermis culture model. By using this model, we can mimic the mechanism of arsenic-induced skin diseases. Which will give us much more information that similar to carcinogenesis progesee in human body as compared to cell culture model. The effects of arsenic on epidermis formation, the effects of UVB and arsenic on arsenical carcinogenesis and the interactions between immune cells and skin cells will be studied in this 3-year proposal as described below:

The 1st year: Study of arsenical effects on integrin expression, cell proliferation, differentiation and apoptosis in organotypic epidermis.

The 2nd year: Study of arsenic and/or UVB –induced biological changes in organotypic epidermis and Bowen’s disease.

The 3rd year: Study of the interactions between immune cells and epidermal cells induced by arsenic.

This study will give us much more information that similar to carcinogenesis progesee in human body as compaired to cell culture model. We hope the result of this study can provide a useful model in chemical carcinogenesis investigation field.

  Eligibility
Ages Eligible for Study:   20 Years to 40 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Criteria

Inclusion Criteria:

Normal healthy adult -

Exclusion Criteria:

systemic disease or with a history of exposure to arsenic-

  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00166946

Contacts
Contact: Hsin-Su Yu, MD PHD     886-2-23562141     dermyu@ha.mc.ntu.edu.tw    

Locations
Taiwan
National Taiwan University Hospital     Recruiting
      Taipei, Taiwan, 100
      Contact: Hsin-Su Yu, MD PHD     886-2-23562141     dermyu@ha.mc.ntu.edu.tw    
Taiwan, Taiwan, Province of China
National Taiwan University Hospital     Suspended
      Taipei, Taiwan, Province of China, Taiwan, 100

Sponsors and Collaborators
National Taiwan University Hospital

Investigators
Study Director:     Hsin-Su Yu, MD PHD     National Taiwan Univesity Hospital, Dept. of Dermatology    
  More Information


Study ID Numbers:   9361701179
First Received:   September 12, 2005
Last Updated:   December 20, 2005
ClinicalTrials.gov Identifier:   NCT00166946
Health Authority:   Taiwan: Department of Health

Study placed in the following topic categories:
Bowen's Disease
Carcinoma, squamous cell
Bowen's disease
Neoplasms, Squamous Cell
Carcinoma, Squamous Cell
Neoplasms, Glandular and Epithelial
Carcinoma

Additional relevant MeSH terms:
Neoplasms
Neoplasms by Histologic Type

ClinicalTrials.gov processed this record on October 06, 2008




Links to all studies - primarily for crawlers